What Happened

A 60-year-old Massachusetts pharmacist pleaded guilty on August 17, 2026 to diverting controlled prescription drugs while working as a per-diem pharmacist at a North Country Healthcare pharmacy in Lancaster, New Hampshire.

She was the only pharmacist on duty from August 6 to 9, 2024. During her time at the pharmacy, more than a dozen different types of medication — including stimulants and benzodiazepines — were discovered missing. Security camera footage showed her opening medication bottles and ingesting some of the medication while at work, and concealing pills — placing a tablet in a book that went into her purse, and doing the same with tissues.

The pharmacy's compliance team had noticed signs of suspicious behavior, and the company that owned and managed the pharmacy reported the possible misuse to the DEA and fired the pharmacist for cause. She waived her right to have the matter presented to a grand jury and pleaded guilty to an information charging her with acquiring or obtaining possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge under 21 U.S.C. § 843(a)(3). Sentencing is scheduled for November 23, 2026, and she faces up to four years in prison.

The investigation was led by the DEA and the FDA's Office of Inspections and Investigations.

What Went Wrong

This case shows how quickly a single point of failure can translate into sustained diversion when a pharmacy's controls depend on the person being watched:

  • Solo coverage created an unobserved window. As the only pharmacist on duty, she controlled the drug stock, the dispensing workflow, and the records during the diversion window — with no peer to witness or challenge her access.
  • The shortage was not caught in real time. More than a dozen medication types went missing over a four-day period; it was the management company's compliance team and camera review that surfaced the conduct, not a same-day count.
  • Deliberate concealment was visible on camera. Pills placed in a book and in tissues are the hallmark of knowing diversion, not an inventory error — but the footage was only reviewed after the fact.
  • Personal-use diversion of stimulants and benzodiazepines. These are among the most commonly diverted drug classes in pharmacy practice and among the fastest for patients to notice missing.

How It Could Have Been Prevented

  • Count and reconcile high-risk controlled substances at every shift change — especially when a per-diem or temporary pharmacist is the sole person on duty. A start-of-shift and end-of-shift count of stimulants and benzodiazepines would have surfaced the shortage within hours.
  • Require two-person integrity for high-risk functions during solo shifts — have a technician or manager witness access to high-value stock and document the count.
  • Review camera footage proactively for flagged shifts — per-diem coverage, shortage history, or behavioral concerns — rather than only after an incident.
  • Vet and monitor temporary staff: per-diem and locum pharmacists are a recognized diversion risk population. Onboarding should include controlled-substance policy sign-off, and their shifts should get extra reconciliation scrutiny.
  • Turn behavioral observations into action. The compliance team noticed suspicious behavior; a documented behavioral-observation protocol makes that a formal, timely review instead of a memory.
  • Report promptly and preserve evidence. The management company reported to the DEA and preserved the footage — the correct response. Codify who reports a theft or significant loss, within what time frame, and what evidence to preserve.

Related Guidance

Sources